SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

SAB Biotherapeutics, Inc. (SABS) News

Follow SAB Biotherapeutics, Inc. (SABS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol SABS Asset equity Sector Markets 90 days 5 Last 2.82 Updated Nov 05, 2026, 12:42 PM UTC Open live news feed Open SABS chart & news
M SAB Biotherapeutics Reports Third-Quarter 2026 Loss SAB Biotherapeutics reported no revenue in the quarter, unchanged from a year earlier, and swung to a loss from income. The headline reports EPS of ($0.24). EQUITY | Nov 05, 2026, 12:42 PM UTC M SAB BIO Reports Q3 2026 Financial Results and Business Highlights Adult and adolescent cohorts are fully enrolled in the registrational SAFEGUARD study of SAB-142. EQUITY | Nov 05, 2026, 12:30 PM UTC M SAB Biotherapeutics to Host Q3 2026 Results Call November 5 SAB Biotherapeutics said it will host its third-quarter 2026 financial results conference call and webcast on November 5, 2026, at 8:30 a.m. ET. EQUITY | Oct 29, 2026, 12:37 PM UTC L SABS pivotal study for SAB-142 advances; enrollment due Q4 2026 SafetyGUARD pivotal study for SAB-142 is on track, with last patient enrollment expected in Q4 2026 and top-line data in the second half of 2027. The company says it is funded through 2028. MACRO | Sep 10, 2026, 04:41 PM UTC L SAB Biotherapeutics to take part in upcoming investor conferences SAB Biotherapeutics, Inc. (Nasdaq: SABS) said members of its management team will participate in upcoming investor conferences. EQUITY | Sep 01, 2026, 12:37 PM UTC M SABS: Barclays Initiates Overweight Barclays initiates coverage on SAB Biotherapeutics with an Overweight rating and a price target of $13 EQUITY | Jun 24, 2026, 06:50 PM UTC